Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuma Oyama

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
European Heart Journal|August 24, 2021
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
European Journal of Preventive Cardiology|June 16, 2026
Early versus delayed evolocumab treatment and complex coronary artery revascularizationPaul M Haller, Prakriti Gaba, Colleen Thomas, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 13, 2021
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) TrialAnthony C Keech, Kazuma Oyama, Peter S Sever, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
European Heart Journal|August 24, 2021
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
European Journal of Preventive Cardiology|June 16, 2026
Early versus delayed evolocumab treatment and complex coronary artery revascularizationPaul M Haller, Prakriti Gaba, Colleen Thomas, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 13, 2021
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) TrialAnthony C Keech, Kazuma Oyama, Peter S Sever, et al.
Pageof 3